DAVITA HEALTHCARE PARTNERS's gross profit margin for the third quarter of its fiscal year 2015 is essentially unchanged when compared to the same period a year ago. The company has grown its sales and net income during the past quarter when compared with the same quarter a year ago, and although its growth in net income has outpaced the industry average, its revenue growth has not. DAVITA HEALTHCARE PARTNERS has strong liquidity. Currently, the Quick Ratio is 1.72 which shows the ability to cover short-term cash needs. The company's liquidity has increased from the same period last year.
During the same period, stockholders' equity ("net worth") has remained unchanged from the same quarter last year. The key liquidity measurements indicate that the company is unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q3 FY15||Q3 FY14|
|Net Sales ($mil)||3525.67||3251.82|
|Net Income ($mil)||215.87||184.12|
|Balance Sheet||Q3 FY15||Q3 FY14|
|Cash & Equiv. ($mil)||1970.27||1669.16|
|Total Assets ($mil)||18894.83||18101.42|
|Total Debt ($mil)||9196.71||8502.43|
|Profitability||Q3 FY15||Q3 FY14|
|Gross Profit Margin||29.06||28.45|
|Return on Assets||2.56||4.01|
|Return on Equity||9.69||14.62|
|Debt||Q3 FY15||Q3 FY14|
|Share Data||Q3 FY15||Q3 FY14|
|Shares outstanding (mil)||211.01||214.88|
|Div / share||0.0||0.0|
|Book value / share||23.65||23.15|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||1174438.0||1003518.0|
BUY. DAVITA HEALTHCARE PARTNERS's P/E ratio indicates a significant premium compared to an average of 21.67 for the Health Care Providers & Services industry and a significant premium compared to the S&P 500 average of 21.93. To use another comparison, its price-to-book ratio of 3.10 indicates a premium versus the S&P 500 average of 2.77 and a discount versus the industry average of 4.10. The current price-to-sales ratio is well below the S&P 500 average, but above the industry average. The valuation analysis reveals that, DAVITA HEALTHCARE PARTNERS seems to be trading at a premium to investment alternatives within the industry.
|DVA 32.98||Peers 21.67||DVA 14.76||Peers 12.68|
Premium. A higher P/E ratio than its peers can signify a more expensive stock or higher growth expectations.
DVA is trading at a significant premium to its peers.
Premium. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
DVA is trading at a premium to its peers.
|DVA 18.01||Peers 17.58||DVA 2.50||Peers 1.48|
Premium. A higher price-to-projected earnings ratio than its peers can signify a more expensive stock or higher future growth expectations.
DVA is trading at a premium to its peers.
Premium. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
DVA trades at a significant premium to its peers.
|DVA 3.10||Peers 4.10||DVA -34.13||Peers 37.68|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
DVA is trading at a discount to its peers.
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
However, DVA is expected to significantly trail its peers on the basis of its earnings growth rate.
|DVA 1.14||Peers 0.79||DVA 8.34||Peers 15.65|
Premium. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
DVA is trading at a significant premium to its industry.
Lower. A sales growth rate that trails the industry implies that a company is losing market share.
DVA significantly trails its peers on the basis of sales growth
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas